Zevra Therapeutics, Inc. (ZVRA)

Over the past six months, Zevra Therapeutics' stock price has been influenced by several events. Presentations at the WORLDSymposium and a Nasdaq bell ceremony led to positive reactions. Conversely, a distribution agreement for MIPLYFFA outside Europe and inducement equity grants resulted in slight stock declines. The company's Q3 2025 earnings showed an EPS beat but a revenue miss, while Q2 earnings surpassed revenue estimates due to a gain on the sale of a priority review voucher.

Zevra Therapeutics' stock has shown some seasonality, with February historically having a 41.67% probability of a positive return, while June has demonstrated the highest probability of positive returns at 61.54%.

Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases. Its portfolio includes commercial products like MIPLYFFA for Niemann-Pick disease type C and OLPRUVA for urea cycle disorders, as well as clinical candidates like Celiprolol for Vascular Ehlers-Danlos Syndrome and KP1077 for rare sleep disorders. AZSTARYS is also listed among its development assets for the treatment of attention deficit and hyperactivity disorder.

Zevra Therapeutics primarily generates revenue from MIPLYFFA and OLPRUVA sales in the United States. The company has also received revenue from the French Accès Compassionnel program for arimoclomol and is actively seeking geographic expansion opportunities.

Zevra Therapeutics has focused on its mission to bring life-changing therapeutics to people with rare diseases, emphasizing data-driven development and patient needs. Presentation of data for MIPLYFFA at the WORLDSymposium positively impacted its reputation. However, the market has considered execution risks, CFO transition, the impact of one-off gains, and challenges of commercializing therapies for ultra-rare diseases globally.

Zevra Therapeutics, Inc. has significant institutional ownership, with 251 institutional owners and shareholders holding 43,322,456 shares. Major institutional shareholders include BlackRock, Inc., Woodline Partners LP, and The Vanguard Group Inc., collectively holding a substantial portion of the company's shares.